

¹ Institute Oswaldo Cruz, Fiocruz, National Reference Laboratory for Viral Hepatitis, Rio de Janeiro, Brasil

² Institute Oswaldo Cruz, Fiocruz, Technological Development Laboratory, Rio de Janeiro, Brasil

³ Institute Oswaldo Cruz, Fiocruz, Molecular Virology and Parasitology Laboratory, Rio de Janeiro, Brasil

⁴ Hospital Nossa Senhora das Graças, Gastroenterology, Hepatology and Liver Transplantation Service, Curitiba, Brasil

Introduction and Objectives: Covid-19 presents as a multisystemic disease with described liver impact. MicroRNAs (miRNAs) are small non-coding RNAs which regulate different pathological processes, including hepatic conditions associated with SARS-CoV-2 infection. This study aimed to investigate serum miRNAs expression in patients with liver diseases according to the presence of SARS-CoV-2 infection.

Materials and Methods: Serum were obtained from 70 individuals from 4 groups: (i) hepatitis/Covid-19 (n=11); (ii) hepatitis-only (n=20); (iii) Covid-19-only (n=19) and (iv) control subjects without both infections (n=20). MiRNAs were isolated from the samples using a commercial extraction kit. After reverse transcription, three miRNAs (mir122, mir143 and mir223) and exogenous control (mir39) were evaluated using relative quantification by real-time PCR. Statistical analysis was made using GraphPad Prism 9.5.1 software.

Results: There was a higher expression of mir122 in the liver disease group when compared to other groups. Statistical significance was founded in the lower expression of mir143 for hepatitis/covid group when compared to control (relative quantification average=0.55 vs. 2.10, $p=0.0094$) and covid-19-only (relative quantification average=0.55 vs. 3.19, $p=0.0037$). Mir223 showed a lower expression in groups composed of liver patients, with or without covid-19. Also, a statistical significance was observed for hepatitis-only group when compared to control (relative quantification average=1.1 vs. 7.52, $p=0.0406$) and covid-19-only (relative quantification average=1.1 vs. 12.94, $p=0.0268$). The same was suggested for hepatitis/covid-19 group when compared to control (relative quantification average=1.1 vs. 7.52, $p=0.0009$) and covid-19-only (relative quantification average=1.1 vs. 12.94, $p=0.0006$).

Conclusions: The different expression of these miRNAs has already been described in association with liver conditions. The description of the different expression of these markers will contribute to future studies that will evaluate associations with predispositions to clinical worsening, inflammation, or therapeutic failure in liver patients with covid-19.

<https://doi.org/10.1016/j.aohep.2023.101238>

P- 52 CORRELATION AMONG DIFFERENT METHODS TO ESTIMATE BODY AND LIVER FAT IN HEALTHY ADULTS

Sophia Eugenia Martínez¹, Ashuin Kammar², Carlos Moctezuma³, Graciela Elia Castro¹, Luis Uscanga¹

¹ Gastroenterology Department, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Ciudad de México, México

² Research Division, National Institute of Geriatrics, Ciudad de México, México

³ Liver Unit, University of Alberta, Edmonton, Canadá

Introduction and Objectives: An increase in body fat is a risk factor to develop fatty liver disease. Until now, few studies have related different methods to estimate body fat related to liver fat. We aimed to

determine the correlation among different methods to estimate body and liver fat in healthy adults.

Materials and Methods: In a cross-sectional study registered in ethics and research committees GAS3794 evaluating healthy adults; chronic illness, uncontrolled diabetes, hypertension or thyroid, bariatric surgery or pacemaker, were not included. The estimation of body fat (BF) was by 3 methods, two with bioelectric impedance of 19 frequencies (19F), 4 frequencies (4F) and the third by the Durnin-Womersley (DW) skinfold thickness formulae; also, were measured body mass index (BMI), waist circumference (WC) and visceral fat (VF). The liver fat was estimated by controlled attenuation parameter (CAP) using transitory elastography. Correlations were calculated with Pearson coefficient among body composition methods and CAP; each anthropometric isolated parameter was associated with hepatic steatosis grades by a logistic regression analysis using SPSS v21.0.

Results: In 231 participants, mean age was 41.8 years (SD 11.3), WC 91 cm (SD 12), BMI 27.8 kg/m² (SD 4.6). 112 had some grade of steatosis (S3 n=72, S2 n=18). The correlation among 3 methods was on average $r=0.853$ ($p=0.000$), and between CAP and BF was 0.290 ($p=0.000$). BMI, WC, VF and suprailiac skinfold thickness showed correlations of $r=0.570$ ($p=0.000$), $r=0.477$ ($p=0.000$), $r=0.393$ ($p=0.000$) y $r=0.471$ ($p=0.000$) respectively. Regression analysis demonstrated that BMI (OR=1.32, $p=0.000$), WC > 80 women and > 90 cm men (OR=14.7, $p=0.010$), VF (OR=1.8, $p=0.008$) and suprailiac skinfold thickness (OR=1.14, $p=0.000$) showed association with steatosis.

Conclusions: Three methods were like to estimate body fat although they were not able to represent the liver fat; waist circumference was the best indicator related with steatosis

<https://doi.org/10.1016/j.aohep.2023.101239>

P- 53 NATURAL KILLER CELLS OF EARLY STAGES OF METABOLIC FATTY LIVER DISEASE PRESENT REDUCED CYTOTOXICITY AGAINST TUMOR CELLS. CASE- CONTROL ANALYSIS

Nixa Paola Olivares¹, Daniel Ernst², Maria Cecilia Poli², Gustavo Pinto², Francisca Allendes¹, Vanessa Oyarzún¹, Nancy Solis¹, Marco Arrese¹, Juan Pablo Arab¹, Daniel Cabrera¹, Luis Antonio Diaz¹, Francisco Barrera¹

¹ Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

² Program of Immunogenetics and Translational Immunology, Institute of Science, Clínica Alemana Universidad Del Desarrollo, Santiago, Chile


Introduction and Objectives: The liver is considered an important immunological site where natural killer (NK) cells mediate the immune response and tumoral immune surveillance. Understanding the involvement of NK cell function at different stages of metabolic fatty liver disease (MAFLD) is crucial to understand the oncogenic risk of MAFLD and hepatocellular carcinoma (HCC) carcinogenesis. This study aims to characterize the phenotype and function of peripheral NK cells in subjects with different stages of MAFLD.

Materials and Methods: We recruited 15 patients with non-cirrhotic MAFLD (NC-MAFLD), 18 with cirrhosis (CR-MAFLD), and 7 with HCC and compared them with 10 control subjects (HD). Peripheral blood NK cell analysis was performed using multiparametric flow cytometry to characterize NK cells in terms of maturation and function. LDH (lactate dehydrogenase) release assay was used to assess cytotoxicity against tumor cells in isolated NK cells. The results are expressed in percentages in Figure 1 with statistical analysis.

Results: NK cells from patients with NC-MAFLD have a significantly lower cytotoxic capacity than controls (HD=89.7% vs.

MAFLD=54.06%, $p=0.0115$). CD107a, a marker of NK cell degranulation, was significantly reduced in NC-MAFLD and CR-MAFLD after exposure to tumor cells. IFN- (cytotoxicity marker) is reduced in all three MAFLD groups compared to HD. Activation of NKG2D and CXCR3 receptors is significantly decreased in all three MAFLD groups compared to controls, while CD69 is decreased in NC-MAFLD and CR-MAFLD. In addition, the NKG2A (inhibitory receptor) is also decreased (Figure N°1, attached). Markers known to be involved in the NK cell apoptosis process, TRAIL, and FASL, are increased in the cirrhosis and HCC group.

Conclusions: These results suggest that early stages in patients with MASLD (particularly NC-MAFLD) have NK cell dysfunction with reduced cytotoxic capacity and activating receptors. These findings suggest NK cells exhaustion could be present in early stages of MASLD.



<https://doi.org/10.1016/j.aohep.2023.101240>

P-54 EVALUATION OF DAILY CLINICAL PRACTICE IN A CENTRAL AMERICAN COHORT WITH A DIAGNOSIS OF AUTOIMMUNE LIVER DISEASE: THEORY VS. PRACTICE

Alejandra Ochoa, Rosemary Sawyers, Aldo Carvajal, Álvaro Villabos, Óscar González, Carlos Campos, Mario Láscarez, Alessia Ávalos, Rolando Páez, Gerardo Avendaño, Pablo Coste

Gastroenterology and Liver Transplant Program, Calderon Guardia Hospital, San Jose, Costa Rica

Introduction and Objectives: Autoimmune liver diseases (AILD) are entities of uncertain cause that affect all ages, genders, and ethnicities. Timely treatment drastically modifies the prognosis, but epidemiological heterogeneity represents a challenge. Adherence to international guidelines for its management is especially important for liver transplantation programs. This study aims to establish the epidemiological profile of a Central American cohort and analyze adherence to diagnostic and therapeutic guidelines in the specialized clinical practice of a Liver Transplant center.


Materials and Methods: Observational, retrospective study of a cohort diagnosed as AILD based on the digital records of a specialized hospital: autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and variant syndromes.

Results: From 1998-2021, 52 patients were identified: 42% HAI, 19% CEP, 12% CBP, 21% HAI+CBP, 6% HAI+CEP. Mean age: 59 years (SD +/-12.2), 81% women. The main comorbidities were autoimmune diseases 52% (Hashimoto's thyroiditis 19%, Sjögren's 10% and rheumatoid arthritis 10%). Liver biopsy was performed in 25 patients (48%) (F3+F4: 16%). The serological study with antibodies and IgGs was requested in 60% of those classified as HAI, the simplified score for HAI was calculated in 55% (9% probable, 0% definitive) and one of 11

(9%) patients classified as HAI+CBP fulfilled the Paris criteria. Thirty-six percent of patients classified as HAI were treated according to current guidelines (37% complete response and 31% partial response) and all PBC and PSC were treated with ursodeoxycholic acid. Female sex and histological grade of fibrosis were significantly associated with better response to HAI treatment ($p=0.003$ and $p=0.044$, respectively).

Conclusions: A high percentage of patients approached as AILD in daily clinical practice does not conform to established guidelines and is based on individualized medical judgment. The application of protocolized guidelines for the management of AILD minimizes the possibility of etiologic overdiagnosis.

FIGURE 1: Diagnostic and therapeutic approach to patients with autoimmune liver diseases



<https://doi.org/10.1016/j.aohep.2023.101241>

P- 55 ACUTE LIVER FAILURE IN PERU: EPIDEMIOLOGY AND PROBLEMATIC OF SUPPORT AND MANAGEMENT

P. Martin Padilla¹, Carmen Cerron¹, Jaime Zegarra², Gustavo Matias¹, Mayra Galindo¹, Gelsing Vásquez³, Anderson Solano⁴, Javier Chian⁵, Lorena Castro⁶, Catherine Peña⁷, Oscar Canchari⁸, Yessica Castillo⁸, Marilia Montes de Oca⁹, William Condori³, Pierre Azabache¹, Liliana Chambi¹⁰, Angel Bardales¹¹, Lida Castillo⁵, Walter Manrique¹¹, Wilhelm Bauercordova¹², Steephany Sanchez¹³, Zully Placido⁶, Katia Acuña¹⁴, Walter Diaz⁷, Katherine Zevallos¹⁵, Raul Castro¹⁵, Manuel Munaico⁶, Juan De la Cruz¹⁶, Albel Sanchez¹, Rosa Lopez¹

¹ Unidad de Hígado, Hospital Nacional Guillermo Almenara. EsSalud, Lima, Perú

² UCI, Clínica Sanna San Borja, Lima, Perú

³ UCI, Instituto Materno Perinatal, MINSA, Lima, Perú

⁴ UCI, Hospital Ramón Castilla, EsSalud, Lima, Perú

⁵ UCI, Hospital de Alta Complejidad Virgen de la Puerta, EsSalud, Trujillo, Perú

⁶ UCI, Hospital Nacional Edgardo Rebagliati, EsSalud, Lima, Perú

⁷ Emergencia, Hospital Central de la Policía, PNP, Lima, Perú

⁸ UCI, Hospital Emergencias Ate, EsSalud, Lima, Perú

⁹ Medicina Interna, Hospital III Iquitos, EsSalud, Puno, Perú

¹⁰ Medicina Interna, Hospital Nacional Hipólito Unanue, MINSA, Lima, Perú